Sturm, Ruger Feeling the Effects of Desperate Rivals
While demand has picked up, heavy promotional activity in the industry remains a headwind.
Repligen Signals Gene Therapy Strength With 2019 Earnings Report
Guidance for 2020 appears to have spooked investors, but the bioprocess leader is on a solid long-term trajectory.
McDonald's Serving Up Fast-Food-Scented Candles
The world's biggest restaurant chain's newest product lets consumers enjoy the smell of a Quarter Pounder without the calories.
Experts say that bitcoin will either become a value store comparable to gold or die trying. Here's how far it would have to climb to reach that goal.
The online real estate site keeps downplaying this potentially industry-shaking move.
Amazon's AWS could be outpaced by rivals and end up losing market share in the cloud.
If you thought things couldn't get worse for pot stocks, think again.
And it's a huge indication that countless seniors are making a very big mistake when claiming benefits.
Gilead Sciences has drawn attention to itself with a possible coronavirus treatment -- but that isn’t the main reason to invest in the company.
Select your professional references carefully.
After better-than-expected fiscal second-quarter results, the company's stock price dropped by more than 10%, but its valuation remains high.
Marathon Oil thinks it can continue generating and returning a gusher of free cash flow to its investors.
Why let your money sit around, goofing off, doing little for you, when those dollars could get jobs and bring home some additional dollars?
The cosmetics company looks to appeal to Gen Z buyers with a celebrity brand acquisition.
This may be one of the most attractive risk-reward investments available today.
Younger Americans are far from worry-free when it comes to money. Here's what's on their minds.
Which of these two small-cap gene-editing stocks is a better investment?
The cosmetics company seems to be gaining after cutting loose from brick-and-mortar.
Can these high-flying biotech stocks keep up their sizzling momentum?
The presidential candidate paid more in tax in 2018, but her family also earned more income.
Success for the Celgene merger rests heavily on new drug approvals the U.S. Food and Drug Administration could deliver in March.
Here's how to manage your investments during your senior years.
The pizza joint benefited from third-party food delivery apps battling one another.